Kathleen Brady
Family · Syracuse, NYNPI 1386166379
Payments from drug & device makers
Across 181 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$689
- Genentech USA, Inc.$629
- Pfizer$432
- Lundbeck LLC$221
- Jazz Pharmaceuticals Inc.$154
- Amgen$146
- plus $807 from 14 others
What the payments were for
- Food & beverage$3,077100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $689 |
| Genentech USA, Inc. | 33 | $629 |
| Pfizer | 37 | $432 |
| Lundbeck LLC | 10 | $221 |
| Jazz Pharmaceuticals Inc. | 5 | $154 |
| Amgen | 8 | $146 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $138 |
| Eisai Inc. | 2 | $137 |
| TG Therapeutics, Inc. | 5 | $96 |
| Neurocrine Biosciences, Inc. | 3 | $74 |
| Lilly USA, LLC | 3 | $59 |
| Argenx US, Inc. | 3 | $56 |
| Averitas Pharma Inc. | 2 | $49 |
| UCB, Inc. | 2 | $49 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$116
How this compares
$3,077 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 47 | $33,779 |
| Nurtec OdtRimegepant Sulfate | 24 | $32,505 |
| BriviactBrivaracetam | 17 | $26,457 |
| UbrelvyUbrogepant | 17 | $14,223 |
| Lacosamide | 45 | $5,859 |
| Gabapentin | 45 | $3,866 |
| Clonazepam | 174 | $3,380 |
| Tegretol XrCarbamazepine | 11 | $3,209 |
| Pregabalin | 79 | $2,640 |
| Divalproex Sodium | 41 | $2,598 |
| Phenobarbital | 99 | $2,132 |
| Primidone | 80 | $2,048 |
| Topiramate | 102 | $1,902 |
| Rasagiline Mesylate | 16 | $1,695 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $1,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $432 | $32,50524 claims |
| UCB, Inc.Briviact | $49 | $26,45717 claims |
| AbbVieUbrelvy | $689 | $14,22317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.
Other family in Syracuse
- Jonathan LesuerSyracuse$172K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.